Ascend Capital’s Loxo Oncology, Inc LOXO Stock Holding History

Ascend Capital’s Portfolio LOXO Stock Details LOXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-70,000	Closed	-$871K	–	210
2015 Q1	$871K	Buy	+70,000	New	+$872K	0.03%	154

Other funds holding LOXO

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Ascend Capital's LOXO Position: Q2 2015 in Review

Ascend Capital sold out of Loxo Oncology, Inc (LOXO) in Q2 2015, closing a stake of 70,000 shares — an estimated $871K sold.

Ascend Capital first reported a position in LOXO in Q1 2015 and held it in 1 quarter. The position peaked at $871K in Q1 2015. 50 funds tracked by Wall St. Rank hold LOXO as of Q2 2015.

Ascend Capital reported no remaining Loxo Oncology, Inc position as of Q2 2015 after selling out during the quarter.
Ascend Capital sold 70,000 Loxo Oncology, Inc shares in Q2 2015, an estimated $871K.
Ascend Capital first reported a position in Loxo Oncology, Inc in Q1 2015 and held it in 1 quarter.
Ascend Capital's Loxo Oncology, Inc position peaked at $871K in Q1 2015.
50 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q2 2015.

Based on Ascend Capital's 13F filing for Q2 2015, filed 13 Aug 2015.